Compagnie Lombard Odier SCmA’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-150	Closed	-$4K	–	615
2018 Q4	$4K	Hold	150	–	–	﹤0.01%	520
2018 Q3	$9K	Hold	150	–	–	﹤0.01%	518
2018 Q2	$11K	Hold	150	–	–	﹤0.01%	549
2018 Q1	$10K	Sell	150 -150	-50%	-$11.3K	﹤0.01%	549
2017 Q4	$26K	Buy	300 +150	+100%	+$14.7K	﹤0.01%	572
2017 Q3	$17K	Hold	150	–	–	﹤0.01%	618
2017 Q2	$18K	Buy	+150	New	+$18.6K	﹤0.01%	623
2016 Q2	–	Sell	-100	Closed	-$9K	–	992
2016 Q1	$9K	Buy	+100	New	+$10.9K	﹤0.01%	897

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Compagnie Lombard Odier SCmA's BLCM Position: Q1 2019 in Review

Compagnie Lombard Odier SCmA sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2019, closing a stake of 150 shares — an estimated $4K sold.

Compagnie Lombard Odier SCmA first reported a position in BLCM in Q1 2016 and held it in 8 quarters. The position peaked at $26K in Q4 2017. 94 funds tracked by Wall St. Rank hold BLCM as of Q1 2019.

Compagnie Lombard Odier SCmA reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 150 Bellicum Pharmaceuticals, Inc. shares in Q1 2019, an estimated $4K.
Compagnie Lombard Odier SCmA first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2016 and held it in 8 quarters.
Compagnie Lombard Odier SCmA's Bellicum Pharmaceuticals, Inc. position peaked at $26K in Q4 2017.
94 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2019.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2019, filed 13 May 2019.